SMMNY (Siemens Healthineers AG) 5-Year EBITDA Growth Rate : 5.60% (As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Siemens Healthineers AG 5-Year EBITDA Growth Rate?

Siemens Healthineers AG's EBITDA per Share for the three months ended in Sep. 2024 was $0.64.

During the past 12 months, Siemens Healthineers AG's average EBITDA Per Share Growth Rate was 11.70% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 5.60% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 5.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 10 years, the highest 3-Year average EBITDA Per Share Growth Rate of Siemens Healthineers AG was 8.80% per year. The lowest was -0.30% per year. And the median was 5.60% per year.

Competitive Comparison of Siemens Healthineers AG's 5-Year EBITDA Growth Rate

For the Medical Devices subindustry, Siemens Healthineers AG's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Siemens Healthineers AG's 5-Year EBITDA Growth Rate Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Siemens Healthineers AG's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Siemens Healthineers AG's 5-Year EBITDA Growth Rate falls into.

Siemens Healthineers AG 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Siemens Healthineers AG (OTCPK:SMMNY) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Siemens Healthineers AG 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Siemens Healthineers AG's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Siemens Healthineers AG Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Siemens Healthineers AG (OTCPK:SMMNY) » Definitions » 5-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

SEMHF:USA 1SHL:Italy SHLd:UK 0PMJ:UK SHL:Germany SHL:Austria

Address

Siemensstr. 3, Forchheim, BY, DEU, 91301

Website

https://www.siemens-healthineers.com

Siemens Healthineers is engaged in therapeutic imaging, radiotherapy, laboratory, and point-of-care diagnostics. The imaging segment (55% of sales in fiscal 2023) includes magnetic resonance imaging, computed tomography, X-ray systems, molecular imaging, and ultrasound. The Varian segment (16% of sales) offers radiotherapy and other oncology solutions. The portfolio of the diagnostics segment (21%) includes in vitro diagnostics products offered to providers and point-of-care diagnostics. The advanced therapies segment (9%) products are designed to support image-guided minimally invasive treatments in cardiology, interventional radiology, and surgery. North America represents 41% of total sales, Europe, Middle East, and Africa 32%, and Asia-Pacific including China the remainder.